Traws药业已成功完成其候选药物Ratutrelvir针对适用与不适用Paxlovid®治疗的新冠肺炎患者的临床研究数据分析。此项分析为评估该药物在不同患者群体中的疗效与安全性提供了关键见解。
同时，公司宣布更新其另一款药物Tivoxavir Marboxil的研发进展，该药物正在寻求作为季节性流感的预防性治疗新适应症。这一进展标志着Traws药业在抗病毒治疗领域同时推进多项研发计划，旨在应对新冠病毒和季节性流感带来的公共卫生挑战。
Traws药业已成功完成其候选药物Ratutrelvir针对适用与不适用Paxlovid®治疗的新冠肺炎患者的临床研究数据分析。此项分析为评估该药物在不同患者群体中的疗效与安全性提供了关键见解。
同时，公司宣布更新其另一款药物Tivoxavir Marboxil的研发进展，该药物正在寻求作为季节性流感的预防性治疗新适应症。这一进展标志着Traws药业在抗病毒治疗领域同时推进多项研发计划，旨在应对新冠病毒和季节性流感带来的公共卫生挑战。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.